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SERUM PROSTATE-SPECIFIC
ANTIGEN AS SURROGATE FOR THE
HISTOLOGICAL DIAGNOSIS OF
PROSTATE CANCER
C F Heyns, A M audt'!, G Ahmed, H B Stopforth,
G A Stellmacher, A J Visser
Introduction. To determine whether there is a cut-off value of
serum prostate-specific antigen (PSA) which can be used
confidently to make the diagnosis of prostate cancer,
thereby obviating the need for biopsy.
Patients and methods. During the period October 1991 to
March 1998 the Department of Chemical Pathology at
Tygerberg Hospital performed a total of 6 733 serum PSA
assays on 3 960 patients. The histopathological and clinical
diagnoses of these patients were obtained from records in
the departments of Anatomical Pathology, Urological
Oncology and Radiation Oncology. The serum PSA levels
were correlated with the histopathology reports, using
different PSA cut-off values ranging from 5 to 500 ng/ml, to
calculate the sensitivity, specificity, and positive and
negative predictive values of each cut-off value of PSA in
predicting the presence of prostate cancer.
Results. In total, 3 837 (57%) of the 6733 serum PSA assays
were ~ 4 ng/ml, 1 045 (15.5%) of the assays were
~ 50 ng/ml, and 798 (11.9%) were ~ 100 ng/ml. Of the total
of 3 960 individual patients, 531 (13.4%) had a serum PSA
~ 50 ng/ml and 423 (10.7%) had a PSA ~ 100 ng/ml. A
serum PSA of ~ 30 ng/ml had a positive predictive value
(PPY) of 90% at a specifidty of 87% and sensitivity of 78%,
while a PSA ~ 60 ng/ml had a PPV of 98% at a specificity of
98% and sensitivity of 65% for the presence of prostate
cancer. The PPV reached 99% at a PSA ~ 100 ng/ml and
100% at a PSA ~ 500 ng/ml, with a specificity of 99% and
100%, but sensitivity of only 53% and 19%, respectively.
Conclusions. A serum PSA ~ 60 ng/ml has a PPV of 98% for
the presence of adenocarcinoma of the prostate, and may be
used as a surrogate for histological diagnosis where
facilities for obtaining prostatic biopsies are not readily
available, thus decreasing costs and patient morbidity.
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The diagnosis of prostate cancer can be suspected on abnormal
digital rectal examination (DRE) or elevated erum prostate-
specific antigen (PSA), but usually histopathological
confirmation of malignancy is required before treatment is
given. I'3 However, prostatic biopsy carries a significant risk of
complications, some of which may be life-threatening'" Also,
in developing countries, especially in rural areas, the human
and technical resourceS to perform prostatic biopsy must be
unavailable. The cost of transferring patients to a centre where
biopsy can be performed may lead to delayed diagnosis or
even non-treatment of the disease. We conducted a
retrospective analysis to determine whether a certain PSA cut-
off level could be used with confidence to establish the
diagnosis of prostate cancer, thereby obviating the need for
biopsy.
PATIE TS A D METHODS
The results of serum PSA assays performed during the period
October 1991 to March 1998 by the Department of Chemical
Pathology at Tygerberg Hospital were obtained (6733 assay
performed on 3 960 patients). The histopathology reports of
patients with a serum PSA ~ 4 ng/ml were obtained, if
available, from the Department of Anatomical Pathology. The
study cohort represents patients referred to Tygerberg Hospital
(a tertiary referral centre) and does not constitute a prostate
cancer screening population.
The serum PSA levels were correlated with the
histopathology reports, using different PSA cut-off values
ranging from 5 to 500 ng/ml, to calculate the sensitivity,
specificity, and positive and negative predictive values (PPV
and NPV) of each cut-off value of PSA in predicting the
presence of prostate cancer. Data analysis was performed using
Excel 2000.
In patients with a PSA > 50 ng/ml, where no pathology
report was available, the patients' clinical data were obtained
from the Urological Oncology Clinic computer databa e, the
Department of Radiation Oncology or the Tygerberg Ho pital
. Records Department. In these patients without pro tatic
histopathology a clinical diagnosis of prostate cancer was made
if there was a DRE fUspicious of malignancy plus radiological
or bone scan evidence of skeletal metastases, an elevated serum
acid pho phatase or serum PSA, clinical response to androgen
ablation, or clinical progression and death consistent with a
diagnosis of prostate cancer.
RESULTS
In total, 3837 (57%) of the 6 733 serum PSA assays were
~ 4 ng/ml, 1 045 (15.5%) of the assays were ~ 50 ng/ml, and
798 (11.9%) were ~ 100 ng/ml. Of the total of 3960 individual
patients, 531 (13.4%) had a serum PSA ~ 50 ng/ml and 423
(10.7%) had a PSA ~ 100 ng/rnl.
.
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Fig. 1. Frequency distribution of PSA values in 716 patients with
PSA ~ 4 ng/ml ::; 6 months before prostate biopsy.
In 716 cases with a PSA ~ 4 ng/ml the date of the serum
PSA assay was::; 6 months before the date of the prostatic
histopathology report. The frequency distribution of PSA
values in this group of 716 patients is shown in Fig. 1. The
sensitivity, specificity, PPV and NPV of PSA at various cut-off
levels were calculated in this group of patients (Table I). A
serum PSA of ~ 30 ng/ml had a PPV of 90% at a specificity of
87% and a sensitivity of 78%, while a PSA ~ 60 ng/ml had a
PPV of 98% at a specificity of 98% and sensitivity of 65% for
the presence of prostate cancer. The PPV reached 99% at a PSA
~ 100 ng/ml and 100% at a PSA ~ 500 ng/ml, with a specificity
of 99% and 100%, but sensitivity of only 53% and 19%,
respectively (Table I).
Table I. Value of various cut-off levels of serum PSA in predicting
a histological diagnosis of prostate cancer
Positive egative
PSA cut-off Sensitivity Specificity predictive predictive
(ng/ml) (%) (%) value (%) value (%)
5 99 8 60 81
10 93 43 70 81
15 88 65 78 79
20 84 75 82 77
25 80 83 87 75
30 78 87 90 74
35 75 90 91 72
40 75 92 93 72
45 73 95 96 71
50 72 96 96 71
60 65 98 98 67
70 62 98 98 65
-
80 59 98 98 65
90 56 99 98 62
100 53 99 99 60
200 37 100 99 53
300 27 100 99 48
400 23 100 99 48
500 19 100 100 47
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The clinical data for the 15 patients with a serum PSA
~ 50 ng/ml and prostatic histology showing no evidence of
malignancy are shown in Table II. Histological examination
revealed only benign prostatic hyperplasia (BPH) in 11
patients, infarction in 2 and prostatitis in 2. However, there was
clinical evidence of prostate cancer in 6 of these patients.
Follow-up was available in only 3 patients, and all had died of
unknown causes.
There were 4 patients with BPH on histological examination
whose serum PSAs came down, respectively, from 400 to
18 ng/ml in 6 weeks, from 66.9 to 32 ng/ml in 7 weeks, from.
52.8 to 8 ng/rnl in 11 weeks (without any surgery) and from 50
to 8 ng/rnl in 17 months after transurethral resection of the
prostate (TURP) (Table II). All 4 patients had presented with
acute retention and were catheterised, but urinary tract
infection was proved in only 1 of 3 who had a urine culture.
In 18 patients with a serum PSA ~ 50 ng/rnl and
histologically confirmed prostate cancer, prior or subsequent
tissue specimens did not show malignancy. Prostatic histology
showed BPH in 12, prostatitis in 2, and was inconclusive in 4
patients in whom prior or subsequent prostatic histology (6
and 12 patients, respectively) showed adenocarcinoma. In the
patients with a serum PSA ~ 50 ng/rnl and initially non-
malignant histology, prostatic cancer was demonstrated
histologically within 1 month in 3 patients, within 1 year in 6
patients, and after 22, 57 and 65 months in 3 patients.
DISCUSSION
The accuracy of clinical diagnosis of prostate cancer based on
DRE ranges from 21% to 53%, which is clearly insufficient for
making treatment decisions.' The specificity of an elevated
serum PSA ranges from 75% to 91%;and the 'PPV from 32% to
47%.' Therefore, histopathological confirmation of the
diagnosis is usually obtained before proceeding to definitive
treatment.
Transrectal needle biopsy of the prostate carries inherent
risks and morbidity, including anxiety (65%), discomfort or
pain during the procedure (86 - 96%), fever (4%), persistent
pain for 1 - 2 days (7 - 48%), rectal bleeding (2 - 40%),
haematuria (13 - 58%), haematospermia (5 - 51%), sexual
impairment or decreased libido (21%), voiding difficulty (25%)
or urinary retention (0.4 - 12%) and infection (2.5 - 27%), which
may be localised to the urinary tract or systemic (0.3 - 5%) and
may lead to septic shock and death.H
Serum PSA is the single test with the highest PPV for
prostate cancer, and its use improves the predictive value of
DRE from 21% to 49%.3.7 Although the sensitivity of an elevated
serum PSA (~4 ng/ml) in predicting prostate cancer is high
(72 - 90%), its specificity is only 75 - 91%). False-positive results
are caused by BPH, acute and chronic prostatitis, acute and
chronic urinary retention, prostatic infarction, procedural
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Table U. Clinical data of patients with prostatic histology showing no malignancy
Age PSA
No. (yrs) Date Clinical presentation Date (ng/ml) Date Histology Date Follow-up
1 80 2/11/88 Prostatitis, MSU culture positive
9/1/89 DRE large BPH
9/12/% Acute retention, catheterised, 11/12/96 400 17/12/% Biopsy = BPH
DRE? BPH? T4 CAP,
MSU culture negative,
bone scan negative
27/1/97 18 22/2/97 Died
2 87 7/5/92 Acute retention, catheterised, 7/5/92 84.5 8/5/92 Biopsy = BPH+
DRE TI CAP, MSU negative, infarction
acid phosphatase normal 15/5/92 RPP=BPH
3 26/8/92 Chronic retention, DRE T3 CAP, MSU 30/8/92 74.5 4/8/88 TURP= BPH
culture positive, acid phosphatase
slightly elevated
10/9/92 TURP=
prostatitis
4 87 9/6/93 Chronic retention, DRE BPH, 6/6/93 93.2 10/6/93 RPP=BPH
MSU culture negative
5 12/8/93 149.6 6/9/93 TURP=BPH
6 75 5/9/94 MSU culture negative 6/7/94 43.7
14/3/95 Bone scan negative 13/3/95 77.45
15/6/95 DRET4CAP 19/6/95 Biopsy = BPH
22/6/95 Ba
7 83 8/6/95 Clinically CAP 25/2/92 22 27/2/92 Biopsy = atypia
4/3/92 TURP=BPH
8/6/95 Ba, clinically
CAP
19/8/97 1140 23/8/97 Died
8 69 24/4/95 Acute retention, catheterised, 24/4/95 47.4
DRE BPH, MSU culture negative
24/6/95 DRE1SOgBPH 23/6/95 66.9
16/8/95 32 18/ /95 RPP= BPH
9 88 26/6/95 ORE TI, MSU culture negative, acid 25/6/95 %.2 27/6/95 Biopsy = BPH
phosphatase elevated, bone scan M1
5/7/95 Biopsy = BPH
10 86 18/3/% Acute retention, catheterised, 17/3/% 190 19/3/% Biopsy = BPH
DRE BPH? TI, MSU culture negative
27/3/% Bone scan? MO 20/3/% TURP= BPH +
infarction
11 68 26/5/% DRE?T3CAP 25/5/97 110 28/5/97 Biopsy = BPH +
prostatitis
4/6/97 Biopsy = BPH
11/6/97 DRE T3 CAP, bone scan? MO 11/6/97 TURP=BPH+
prostatitis
..
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Table 11. Continued
12 76 25/9/96 Chronic retention, catheterised, 24/9/96 107 7/11/96 Biopsy=BPH
DRE BPH, MSU culture negative
30/10/% MSU culture positive 14/11/96 Biopsy=BPH
13 80 9/11/96 Acute retention, DRE 100 g BPH, 8/11/96 52.8 21/11/96 Biopsy=BPH
MSU culture positive
21/11/96 DRE? T3? T4 CAP 29/1/97 8 6/3/97 Biopsy = BPH
3/12/96 Bone scan? M1 1/4/98 Died
14 88 11/11/% 50.6 11/12/% TURP=BPH
15 58 16/2/97 Acute retention, catheterised 13/2/97 50 20/2/97 TURP=BPH
24/7/98 8
MSU =midstream urine; DRE =digital rectal examination; BPH =benign prostatic hyperplasia; CAP =cancer of the prostate; 12, 1'3, T4 =UlCC tumour stage 2,3,4, respectively; RPP =retropubic
prostatectomy; 1URP =transurethral resection of the prostate; BO =bilateral orchidectomy.; MO, M1 =skeletal metastases absent or present, respectively; ? =clinician indicates uncertainty.
~~
intervention (biopsy, TURF, transrectal ultrasound (TRUS»,
while minor elevations are caused by DRE, ambulation,
ejaculation and catheterisation.2.s-12
Serum PSA levels correlate with tumour volume, grade,
stage, lymph node status and metastatic spread."·" A very high.
PSA level is more likely to be due to prostate cancer than any
of the conditions mentioned above, which mostly cause only
mild elevations in serum PSA: In a study of 422 men (350 with
clinically localised, histologically proven prostate cancer and 72
with histologically proven BPH), Partin et al.'~ found that no
patients with BPH and only 1% with organ-confined prostate
cancer had PSA levels ~ 50 ng/rnl.
In a study of 1 749 patients with histologically proven
adenocarcinoma of the prostate seen at our institution between
1976 and 1996, the tumour was locally advanced (stage T3 - T4)
in 64% of cases, and 45% of the patients had skeletal metastases
demonstrated on a radio-isotope bone scan." Therefore, the
high incidence of locally advanced and metastatic prostate
cancer in our patient population explains the fact that, in the
present study, 13.4% of patients had a serum PSA ~ 50 ng/rnl
and 10.7% had a PSA ~ 100 ng/rnl. This is likely to be
representative of most developing countries where early
prostate cancer detection or screening programmes are non-
existent and patients present because of symptoms.
There is very little published information about the
predictive value of high levels of serum PSA. Labrie et al.!6
reported a screening study of 1 002 men aged 45 - 80 years and
calculated the PPV of PSA to be 51% at levels above 10 ng/rnl
and 90% at levels above 30 ng/ml. Grob et al. analysed data on
177 biopsies performed between 1990 and 1997 for PSA
~ 40 ng/rnl. The positive biopsy rate rn patients with PSA
40 - 74.9 ng/rnl was 84%, with PSA 75 - 99.9 ng/ml, 96%, and
with PSA > 100 ng/ml, 98%. They concluded that in men who
are not being offered definitive therapy a PSA > 75 ng/ml is
adequate to establish the diagnosis of prostate cancer (Grob
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B M, Chernoff A, Sherman J, Macchia R J- unpublished
abstract, meeting of the ew York section of the American
Urological Association, October 2000, Cape Town).
The present study indicates that a serum PSA ~ 30 ng/ml
had a PPV of 90% at.a specificity of 87% and sensitivity of 78%,
while a PSA ~ 60 ng/ml had a PPV of 98% at a specificity of
98% and sensitivity of 65% for the presence of prostate cancer.
The PPV reached 99% at a PSA ~ 100 ng/rnl and 100% at a PSA
~ 500 ng/ml, with a specificity of 99% and 100%, but sensitivity
of only 53% and 19%, respectively.
It is interesting to note that in 12 of 18 patients with a serum
PSA ~ 50 ng/ml initial histological examination failed to show
prostate cancer, which was subsequently found in 9 patients
within 1 year of follow-up, and in 3 patients only after 22 - 65
months of follow-up. Therefore, patients with a serum PSA
~ 50 ng/ml should be followed up closely despite initially
negative prostatic biopsy, since the possibility of cancer is very
high. On the other hand, in 4 of our patients with a serum PSA
~ 50 ng/ml and prostatic biopsy showing only BPH the serum
PSA decreased significantly, although it did not return to
normal levels. However, repeat biopsies were not performed in
these patients, and further follow-up may have revealed the
presence of prostate cancer.
In conclusion, our study shows that a serum PSA ~ 60 ng/ml
has a 98% PPV for prostate cancer. Therefore, in selected
patients a very high level of serum PSA may be used as a
surrogate for a histological diagnosis of prostate cancer. 'The
advantage of such an approach would be that the costs and
morbidity of prostatic biopsy could be avoided in this group of
patients.
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COLORECTAL CARCINOMA - A
NEW THREAT TO BLACK PATIENTS?
A RETROSPECTIVE ANALYSIS OF
COLORECTAL CARCINOMA
RECEIVED BY THE INSTITUTE FOR
PATHOLOGY, UNIVERSITY OF
PRETORIA
N Angelo, L Dreyer
Objective. To compare black and white patients with
colorectal carcinoma treated at Pretoria Academic and
Kalafong hospitals, and to compare pathological trends of
our study population with others reported in the literature.
Design. A retrospective study of all cases of resected
colarectal carcinomas received by our department during
the periods 1986 - 1987 (82 cases) and 1996 - 1997 (91 cases).
To investigate variables of age, race and gender distribution
in the two study populations.
Methods. Routinely stained histological sections of all
relevant cases were examined. Findings regarding age,
gender, population group, anatomical location of the
tumour and presence of other pathologicallesians were
recorded. Changes in the referral population and number of
surgical specimens received were also considered during
statistical analysis of the study findings.
Results. There has been a significant increase in the number
of black patients with colorectal carcinoma at our Institute.
In addition, adenomatous polyp were found in 9 of our
black patients (1996/97). Thi i ignificantly higher than
expected from reports in the literature. Thi could be
predictive of an increase in incidence of colorectal
carcinomas in our black population. Black patients were
also found to be considerably younger at age of
presentation than their white counterparts. A further
significant finding Na a con iderable increase in the
number of black females under the age of 40 years from
1986/ 7 to 1996/97. On the other hand, the number of
white females above 40 years of age decreased considerably
over this time. The reason for this finding is uncertain and
warrants further tudy.
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